Biotechnology companies that have previously exclusively sold drugs and vaccines to the federal government are diversifying their businesses to include commercial products, according to a Washington Post article. Steven Overly writes the value of such firms lag compared to commercial counterparts and the defense biotechnology firms are looking to change this. In an example of...